Wedbush reiterates Outperform on Cogent Biosciences, $55 target
Wedbush reiterated an Outperform rating on Cogent Biosciences and set a $55.00 price target, implying 68.0% upside versus the Sep 15 close of $32.74.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.